<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">eClinicalMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EClinicalMedicine</journal-id><journal-title-group><journal-title>eClinicalMedicine</journal-title></journal-title-group><issn pub-type="epub">2589-5370</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9436743</article-id><article-id pub-id-type="pii">S2589-5370(22)00331-5</article-id><article-id pub-id-type="doi">10.1016/j.eclinm.2022.101601</article-id><article-id pub-id-type="publisher-id">101601</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Yamamoto</surname><given-names>Haruko</given-names></name><email>yamamoto-haruko@pmda.go.jp</email><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Suzuki</surname><given-names>Hiroshi</given-names></name></contrib><aff id="aff0001">Pharmaceuticals and Medical Devices Agency, Tokyo, Japan</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author at: Pharmaceuticals and Medical Devices Agency, Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013, Japan. <email>yamamoto-haruko@pmda.go.jp</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>10</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>26</day><month>8</month><year>2022</year></pub-date><volume>52</volume><elocation-id>101601</elocation-id><history><date date-type="received"><day>13</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 The Authors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><related-article related-article-type="article-reference" id="d35e14" ext-link-type="doi" xlink:href="10.1016/j.eclinm.2022.101527"/></article-meta></front><body><p id="para0001">In the recent article of eClinicalMedicine,<xref rid="bib0001" ref-type="bibr"><sup>1</sup></xref> the authors demonstrate that high-dose intravenous immunoglobulin may be effective in recurrent pregnancy losses (RPL). This achievement in an area where double-blind randomised controlled trials are difficult to conduct is to be applauded. On the other hand, we would like to point out two areas in the article that may cause misunderstanding and reduce the value of it.</p><p id="para0002">First, the article refers to the trial as phase II, but the registration details on Clincialtrials.gov<xref rid="bib0002" ref-type="bibr"><sup>2</sup></xref> and the clinical study protocol in the supplementary materials refer to it as phase III, which is inconsistent.</p><p id="para0003">Second, the study protocol clearly states that the primary efficacy analysis set is modified-intention-to-treat (m-ITT), as the target number of patients for efficacy evaluation is set based on the m-ITT.</p><p id="para0004">Although the protocol says that the same analysis will be performed for ITT, we believe that in general, phase III trials should clearly state what the primary efficacy analysis set is and present the main analysis results. The way in which the authors mainly describe the results of the ITT analysis, which is a secondary analysis, might lead to readers&#x02019; misunderstanding.</p><sec id="sec0001"><title>Contributors</title><p id="para0005">H.Y. conceived this manuscript and wrote the original draft. H.S. reviewed and edited this manuscript. All authors accepted responsibility to submit for publication.</p></sec><sec sec-type="COI-statement"><title>Declaration of interests</title><p id="para0006">The authors declare no conflicts of interest associated with this manuscript.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>deguchi</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: a double-blind, randomized, placebo-controlled trial</article-title><source>eClinicalMedicine</source><volume>50</volume><year>2022</year><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101527</pub-id><comment>(Published online 28 June 2022)</comment></element-citation></ref><ref id="bib0002"><label>2</label><mixed-citation publication-type="other" id="sbref0002">Study of the efficacy and safety of GB-0998 in patients with unexplained recurrent miscarriage. Clinicaltrials.gov. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02184741" id="interref0001">https://clinicaltrials.gov/ct2/show/NCT02184741</ext-link>. Accessed online 1 August 2022.</mixed-citation></ref></ref-list></back></article>
